WuXi XDC Cayman (HKG:2268) expects a net profit of 260% higher in 2024 than in 2023, a Wednesday Hong Kong bourse filing said.
The company also expects its revenue for the reporting year to jump 85% compared with the year prior.
The antibody-drug conjugates company attributed the surge in its expected net profit and revenue for the reporting period to steady downstream demand from the fast growth of antibody-drug conjugate and the expanded bio-conjugate industry.
The group also attributed the higher gains for 2024 to its competitive strength and increased profit margins for the reporting period resulting from improved production efficiency.